Acadia Pharmaceuticals’ Immense Opportunities for Stock Surge Acadia’s Nuplazid drug could unlock significant revenue for the company, leading to its stock soaring.
TradeZero Ocean Place Cable Beach, Unit #1 Nassau, Bahamas
In conventional or online stock trading you will come across stocks that may be dull at the time you’re looking at it, but have the potential to surge in the future. Understanding the company’s business strategy and new products that could be potential market scorchers is important to make the winning decision. Ongoing Development Stage Could Bring out a Winning Drug Acadia Pharmaceuticals ($ACAD) stock has great potential to soar because of a drug that could be a potential winner. This drug is in the development process, but if it comes through the trials successfully it could help the company earn billions of dollars. It could give a big boost to the company’s market cap. Acadia stock has not been able to maintain traction this year, and is up by only about 13% though managing to better the S&P 500 marginally. But its recent earnings report has been very promising, and there are many clinical studies going on too that could release some promising drugs into the market. In the second quarter, investors were skeptical on the Nuplazid uptake. That was partly responsible for a short interest. Nuplazid is seeing strong uptake, with the full-year guided revenue of the company rising significantly above the street consensus. www.tradezero.co
+1.954.944.3885
In conventional or online stock trading you will come across Treatment of Parkinson’s Disease Psychosis stocks that may be dull at the time
The key for Acadia lies in the treatment of the disease known as Parkinson’s disease psychosis (PDP). The street is expecting revenue to grow to around $434 million by 2019. With a current market cap of nearly $4 billion, the stock is nearly 10 times its 2019 sales estimates. The Massive Potential for Acadia’s Nuplazid This evaluation also includes the promising pimavenserin drug, called Nuplazid, which is in the development stage in four different studies for treating: • Depression • Alzheimer’s disease agitation • Schizophrenia, and • The negative effects of schizophrenia There is also a fifth study coming, which is for Alzheimer’s disease psychosis. These conditions represent a wide section of the patient population.
www.tradezero.co
+1.954.944.3885
The Market Is Huge fact, the company the you United close to In In conventional or onlinestates stock that trading willStates come has across 400,000 people suffering from PDP. Around 2.7 million people suffer from Alzheimer’s disease with around a half of them suffering from agitation. Alzheimer’s disease psychosis affects nearly 25% to 50% of Americans. With no FDA-approved drugs currently available for these indications, there’s a massive opportunity for Acadia if Nuplazid comes through the development stages of all the studies. Actually, a successful trial in merely one of the aforementioned five indications would significantly increase the market size of the company. Nuplazid has a current $2,133 whole acquisition cost for a supply of 30 days. That gives the drug significant revenue potential. That would be true even if Acadia only managed to get hold of a small section of the market. There’s significant opportunity lying ahead. With experience and insight comes the ability to identify such gold mines in the stock market. Online stock trading is a great way to build up that experience.
www.tradezero.co
+1.954.944.3885